Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 20 de 418 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Espposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, Valgimigli M, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ 2016;354:i4935. [Ref.ID 100794]
2. Cita con resumen
Johnston SC, Amarenco P, Albers GW, Denison H, Easton D, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35-43. [Ref.ID 100628]
3.Enlace a cita original Cita con resumen
Anónimo. Riesgos de los AINE en pacientes que reciben tratamiento antitrombótico. Butlletí Groc 2015;28:5-10. [Ref.ID 99839]
4.Tiene citas relacionadas
Moss JD, Cifu AS. Management of anticoagulation in patients with atrial fibrillation. JAMA 2015;314:291-2. [Ref.ID 99362]
5.Tiene citas relacionadas
Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of atrial fibrillation. JAMA 2015;314:278-88. [Ref.ID 99361]
6.Enlace a cita original Cita con resumen
Montalescot G, Sabatine MS. Oral dual antiplatelet therapy: what have we learnt from recent trials?. Eur Heart J 2015:6 de agosto. [Ref.ID 99343]
7.Tiene citas relacionadas Cita con resumen
Han Y, Guo J, Zheng Y, Zang H, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li Y, Xu B, Stone GW, for the BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015;313:1336-46. [Ref.ID 99015]
8.Tiene citas relacionadas
Cavender MA, Faxon DP. Can BRIGHT restore the glow of bivalirudin?. JAMA 2015;313:1323-4. [Ref.ID 99014]
9.Tiene citas relacionadas Cita con resumen
Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg G, Kerelakes DJ, Yeh RW. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015;385:792-8. [Ref.ID 98826]
10.Tiene citas relacionadas
Lemesle G. Dual antiplatelet therapy and non-cardiovascular mortality. Lancet 2015;385:756-7. [Ref.ID 98825]
12. Cita con resumen
Anónimo. Antithrombotic drugs. Med Lett Drugs Ther 2014;56:103-8. [Ref.ID 98343]
13. Cita con resumen
del Castillo-Carnevali H, Barrios Alonso V, Zamorano Gómez JL. Antiagregación: resistencia a fármacos tradicionales y papel de los nuevos antiplaquetarios. Med Clin (Barc) 2014;143:222-9. [Ref.ID 97903]
14.Enlace a cita original
January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, Conti JB, Ellinior PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Hearth Rhythm Society. Circulation 2014;129:1-107. [Ref.ID 97600]
15.Enlace a cita original Cita con resumen
Anónimo. Clopidogrel: rare reports of acquired haemophilia. United Kingdom. WHO Drug Information 2014;28:23-4. [Ref.ID 97548]
16.
January CT, Wan SL, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and Heart Rhythm Society. Circulation 2014;130:e199-267. [Ref.ID 97389]
17.Tiene citas relacionadas Cita con resumen
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Ioakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-22. [Ref.ID 96586]
18.Tiene citas relacionadas Cita con resumen
May AE. Antiplatelet therapy after coronary stenting: for how long?. Lancet 2013;382:1684-5. [Ref.ID 96584]
20. Cita con resumen
Lee M, Saver JL, Hong K-S, Rao NM, Wu Y-L, Ovbiagele B. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013;159:463-70. [Ref.ID 96342]
Seleccionar todas
 
 1 a 20 de 418 siguiente >>